

# Wei-jin Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4429207/publications.pdf>

Version: 2024-02-01

127  
papers

13,637  
citations

81839

39  
h-index

30058

103  
g-index

151  
all docs

151  
docs citations

151  
times ranked

17325  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. <i>Cell</i> , 2020, 182, 1284-1294.e9.	13.5	1,362
2	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <i>Nature</i> , 2022, 602, 657-663.	13.7	1,350
3	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <i>Nature</i> , 2020, 584, 120-124.	13.7	1,237
4	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 39-51.	4.6	923
5	BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. <i>Nature</i> , 2022, 608, 593-602.	13.7	889
6	Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2020, 9, 680-686.	3.0	638
7	A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. <i>Nature</i> , 2020, 586, 572-577.	13.7	630
8	A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. <i>Cell Host and Microbe</i> , 2020, 28, 124-133.e4.	5.1	540
9	A Thermostable mRNA Vaccine against COVID-19. <i>Cell</i> , 2020, 182, 1271-1283.e16.	13.5	485
10	Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. <i>Science</i> , 2020, 369, 1505-1509.	6.0	358
11	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. <i>Cell</i> , 2021, 184, 2362-2371.e9.	13.5	332
12	Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 134.	7.1	331
13	The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. <i>Emerging Microbes and Infections</i> , 2022, 11, 1-5.	3.0	320
14	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. <i>Nature Protocols</i> , 2020, 15, 3699-3715.	5.5	291
15	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. <i>Cell</i> , 2020, 183, 1013-1023.e13.	13.5	227
16	Circular RNA vaccines against SARS-CoV-2 and emerging variants. <i>Cell</i> , 2022, 185, 1728-1744.e16.	13.5	211
17	High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. <i>Journal of Infection</i> , 2020, 81, 420-426.	1.7	185
18	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 196-208.	4.6	147

#	ARTICLE	IF	CITATIONS
19	Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. <i>Nature</i> , 2022, 603, 919-925.	13.7	146
20	S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. <i>Nature Communications</i> , 2021, 12, 1346.	5.8	133
21	Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. <i>Cell Research</i> , 2021, 31, 732-741.	5.7	124
22	Detection and assessment of infectivity of hepatitis E virus in urine. <i>Journal of Hepatology</i> , 2016, 64, 37-43.	1.8	123
23	Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. <i>Nature Microbiology</i> , 2021, 6, 51-58.	5.9	113
24	Current status on the development of pseudoviruses for enveloped viruses. <i>Reviews in Medical Virology</i> , 2018, 28, e1963.	3.9	112
25	Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. <i>Nature</i> , 0, , .	13.7	90
26	Persistent Hepatitis E Virus Genotype 4 Infection in a Child With Acute Lymphoblastic Leukemia. <i>Hepatitis Monthly</i> , 2013, 14, e15618.	0.1	83
27	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4210.	5.8	82
28	Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. <i>Scientific Reports</i> , 2017, 7, 45552.	1.6	80
29	Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E. <i>Journal of Medical Virology</i> , 2006, 78, 1441-1448.	2.5	72
30	Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 346.	7.1	60
31	Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. <i>Nature Communications</i> , 2020, 11, 5752.	5.8	59
32	Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. <i>Frontiers of Medicine</i> , 2020, 14, 746-751.	1.5	57
33	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	5.7	54
34	Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques. <i>Journal of Medical Virology</i> , 2008, 80, 824-832.	2.5	51
35	Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. <i>Scientific Reports</i> , 2017, 7, 42769.	1.6	50
36	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. <i>Chinese Medical Journal</i> , 2021, 134, 1289-1298.	0.9	49

#	ARTICLE	IF	CITATIONS
37	Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. <i>Communications Biology</i> , 2021, 4, 1196.	2.0	49
38	Hepatitis E Virus Produced from Cell Culture Has a Lipid Envelope. <i>PLoS ONE</i> , 2015, 10, e0132503.	1.1	47
39	The molecular basis for SARS-CoV-2 binding to dog ACE2. <i>Nature Communications</i> , 2021, 12, 4195.	5.8	43
40	A Human DPP4-Knockin Mouse's Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. <i>Viruses</i> , 2018, 10, 448.	1.5	42
41	ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 1488-1499.	3.0	40
42	Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies. <i>Cell Discovery</i> , 2022, 8, .	3.1	40
43	A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 5000.	5.8	37
44	A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1811-1817.	1.4	36
45	Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. <i>Cell Research</i> , 2021, 31, 1130-1133.	5.7	34
46	Asialoglycoprotein receptor facilitates infection of PLC/PRF/5 cells by HEV through interaction with ORF2. <i>Journal of Medical Virology</i> , 2016, 88, 2186-2195.	2.5	30
47	Lentil lectin derived from <i>Lens culinaris</i> exhibit broad antiviral activities against SARS-CoV-2 variants. <i>Emerging Microbes and Infections</i> , 2021, 10, 1519-1529.	3.0	30
48	Hepatitis E genotype 4 virus from feces of monkeys infected experimentally can be cultured in PLC/PRF/5 cells and upregulate host interferon-inducible genes. <i>Journal of Medical Virology</i> , 2014, 86, 1736-1744.	2.5	29
49	Antigenic Drift of Influenza A(H7N9) Virus Hemagglutinin. <i>Journal of Infectious Diseases</i> , 2019, 219, 19-25.	1.9	29
50	Varying abilities of recombinant polypeptides from different regions of hepatitis E virus ORF2 and ORF3 to detect anti-HEV immunoglobulin M. <i>Journal of Medical Virology</i> , 2009, 81, 1052-1061.	2.5	28
51	Virus Host Protein Interaction Network Analysis Reveals That the HEV ORF3 Protein May Interrupt the Blood Coagulation Process. <i>PLoS ONE</i> , 2013, 8, e56320.	1.1	27
52	A Novel High-Throughput Vaccinia Virus Neutralization Assay and Preexisting Immunity in Populations from Different Geographic Regions in China. <i>PLoS ONE</i> , 2012, 7, e33392.	1.1	25
53	Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus. <i>Viruses</i> , 2016, 8, 107.	1.5	25
54	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 18-29.	3.0	25

#	ARTICLE	IF	CITATIONS
55	Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 829-840.	3.0	25
56	Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. <i>National Science Review</i> , 2021, 8, nwa297.	4.6	24
57	Nipah pseudovirus system enables evaluation of vaccines <i>in vitro</i> and <i>in vivo</i> using non-BSL-4 facilities. <i>Emerging Microbes and Infections</i> , 2019, 8, 272-281.	3.0	23
58	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021, 12, 687869.	2.2	23
59	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. <i>Cell Discovery</i> , 2022, 8, 17.	3.1	23
60	An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. <i>Vaccine</i> , 2017, 35, 5172-5178.	1.7	22
61	Comparison of hepatitis E virus genotypes from rabbits and pigs in the same geographic area: No evidence of natural cross-species transmission between the two animals. <i>Infection, Genetics and Evolution</i> , 2013, 13, 304-309.	1.0	21
62	Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. <i>Cell Discovery</i> , 2021, 7, 21.	3.1	20
63	<i>In vitro</i> and <i>in vivo</i> efficacy of a Rift Valley fever virus vaccine based on pseudovirus. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2286-2294.	1.4	19
64	A second functional furin site in the SARS-CoV-2 spike protein. <i>Emerging Microbes and Infections</i> , 2022, 11, 182-194.	3.0	19
65	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 69.	7.1	19
66	Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 199-208.	1.4	18
67	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. <i>Emerging Microbes and Infections</i> , 2021, 10, 1574-1588.	3.0	18
68	Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD. <i>MedComm</i> , 2022, 3, e130.	3.1	18
69	Comparison of the replication characteristics of vaccinia virus strains Guang 9 and Tian Tan <i>in vivo</i> and <i>in vitro</i> . <i>Archives of Virology</i> , 2014, 159, 2587-2596.	0.9	17
70	Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox. <i>Scientific Reports</i> , 2015, 5, 11397.	1.6	17
71	Systematic identification of hepatitis E virus ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF- $\kappa$ B pathway. <i>Virus Research</i> , 2017, 228, 102-108.	1.1	17
72	Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization. <i>Journal of Infectious Diseases</i> , 2017, 216, 867-876.	1.9	17

#	ARTICLE	IF	CITATIONS
73	Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. <i>Journal of Medical Virology</i> , 2014, 86, 1542-1555.	2.5	16
74	Antigenic variations of recent street rabies virus. <i>Emerging Microbes and Infections</i> , 2019, 8, 1584-1592.	3.0	16
75	Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 1390-1403.	3.0	16
76	Hepatitis E virus ORF3 antigens derived from genotype 1 and 4 viruses are detected with varying efficiencies by an anti-Hev enzyme immunoassay. <i>Journal of Medical Virology</i> , 2011, 83, 827-832.	2.5	15
77	The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: Implications for gene therapy and vaccines using AAV1 vector. <i>Journal of Medical Virology</i> , 2013, 85, 1550-1556.	2.5	15
78	Development and application of a bioluminescent imaging mouse model for Chikungunya virus based on pseudovirus system. <i>Vaccine</i> , 2017, 35, 6387-6394.	1.7	15
79	Detection of Hepatitis E Virus in Raw Pork and Pig Viscera As Food in Hebei Province of China. <i>Foodborne Pathogens and Disease</i> , 2019, 16, 325-330.	0.8	15
80	Hepatitis E virus was not detected in feces and milk of cows in Hebei province of China: No evidence for HEV prevalence in cows. <i>International Journal of Food Microbiology</i> , 2019, 291, 5-9.	2.1	14
81	Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. <i>Cell Discovery</i> , 2021, 7, 53.	3.1	14
82	Distinct BCR repertoires elicited by SARS-CoV-2 RBD and S vaccinations in mice. <i>Cell Discovery</i> , 2021, 7, 91.	3.1	12
83	Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults. <i>Cell Research</i> , 2022, 32, 777-780.	5.7	12
84	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. <i>Emerging Microbes and Infections</i> , 2022, 11, 1890-1899.	3.0	12
85	A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 23.	7.1	11
86	INNO-LiPA HBV genotyping is highly consistent with direct sequencing and sensitive in detecting B/C mixed genotype infection in Chinese chronic hepatitis B patients and asymptomatic HBV carriers. <i>Clinica Chimica Acta</i> , 2010, 411, 1951-1956.	0.5	10
87	Absence of hepatitis E virus RNA in semen samples of infertile male in China. <i>Gut</i> , 2020, 69, 1363-1364.	6.1	10
88	HIV-1 pseudoviruses constructed in China regulatory laboratory. <i>Emerging Microbes and Infections</i> , 2020, 9, 32-41.	3.0	10
89	Screening and evaluation of potential inhibitors against vaccinia virus from 767 approved drugs. <i>Journal of Medical Virology</i> , 2019, 91, 2016-2024.	2.5	9
90	Comparison on Virulence and Immunogenicity of Two Recombinant Vaccinia Vaccines, Tian Tan and Guang9 Strains, Expressing the HIV-1 Envelope Gene. <i>PLoS ONE</i> , 2012, 7, e48343.	1.1	9

#	ARTICLE	IF	CITATIONS
91	The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 18.	7.1	9
92	Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. <i>Journal of Infectious Diseases</i> , 2022, 225, 1701-1709.	1.9	9
93	Comparison of Two High-Throughput Assays for Quantification of Adenovirus Type 5 Neutralizing Antibodies in a Population of Donors in China. <i>PLoS ONE</i> , 2012, 7, e37532.	1.1	8
94	Identification of a novel DRB1 allele through intergenic recombination between HLA-DRB1 and HLA-DRB3*02 in a Chinese family. <i>Human Immunology</i> , 2013, 74, 1603-1609.	1.2	8
95	Effect of the maturation of neutralizing antibodies on human immunodeficiency virus (HIV) envelope evolution in HIV-infected subjects. <i>Infection, Genetics and Evolution</i> , 2016, 38, 82-89.	1.0	8
96	Expression and characterization of hepatitis E virus-like particles and non-virus-like particles from insect cells. <i>Biotechnology and Applied Biochemistry</i> , 2016, 63, 362-370.	1.4	8
97	Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging. <i>Scientific Reports</i> , 2017, 7, 3597.	1.6	8
98	Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs. <i>Virologica Sinica</i> , 2020, 35, 235-239.	1.2	8
99	Monitoring Neutralization Property Change of Evolving Hantaan and Seoul Viruses with a Novel Pseudovirus-Based Assay. <i>Virologica Sinica</i> , 2021, 36, 104-112.	1.2	8
100	The first Chinese national standards for SARS-CoV-2 neutralizing antibody. <i>Vaccine</i> , 2021, 39, 3724-3730.	1.7	8
101	Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccinated Immunized Plasma. <i>Advanced Science</i> , 2022, 9, e2104333.	5.6	8
102	Characterization of Chronic Hepatitis E Virus Infection in Immunocompetent Rabbits. <i>Viruses</i> , 2022, 14, 1252.	1.5	8
103	Analysis of the complete genome sequences of one swine and two human hepatitis E virus genotype 4 strains isolated in Beijing, China. <i>Infection, Genetics and Evolution</i> , 2013, 18, 42-47.	1.0	7
104	Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 196.	7.1	7
105	Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients. <i>Small Methods</i> , 2021, 5, 2100058.	4.6	6
106	Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. <i>Antiviral Research</i> , 2021, 194, 105161.	1.9	6
107	Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism. <i>European Journal of Medicinal Chemistry</i> , 2022, 234, 114209.	2.6	6
108	Screening and identification of HTNVpv entry inhibitors with high-throughput pseudovirus-based chemiluminescence. <i>Virologica Sinica</i> , 2022, 37, 531-537.	1.2	6

#	ARTICLE	IF	CITATIONS
109	Analysis of the evolution, infectivity and antigenicity of circulating rabies virus strains. <i>Emerging Microbes and Infections</i> , 2022, 11, 1474-1487.	3.0	6
110	Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12. <i>Virologica Sinica</i> , 2014, 29, 299-307.	1.2	5
111	Structural characterization of a neutralizing mAb H16.001, a potent candidate for a common potency assay for various HPV16 VLPs. <i>Npj Vaccines</i> , 2020, 5, 89.	2.9	5
112	Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19. <i>Vaccine</i> , 2021, 39, 6050-6056.	1.7	5
113	Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. <i>Bioorganic Chemistry</i> , 2021, 115, 105196.	2.0	5
114	The Impact of Natural and Glycosylation Mutations in the SARS-CoV-2 Spike Protein on Viral Infectivity and Antigenicity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
115	Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift. <i>Journal of Medical Virology</i> , 2022, , .	2.5	5
116	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity. <i>Emerging Microbes and Infections</i> , 2022, 11, 1024-1036.	3.0	5
117	Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B <sub>CRF07_AG</sub> molecular clones derived from infections in China. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-13.	3.0	4
118	Clofazimine: A Promising Inhibitor of Rabies Virus. <i>Frontiers in Pharmacology</i> , 2021, 12, 598241.	1.6	4
119	Multiple human papillomavirus infections and type-competition in women from a clinic attendee population in China. <i>Journal of Medical Virology</i> , 2016, 88, 1989-1998.	2.5	3
120	Simultaneous quantification of major capsid protein of human papillomavirus 16 and human papillomavirus 18 in multivalent human papillomavirus vaccines by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2020, 1619, 460962.	1.8	3
121	TIM-1 Augments Cellular Entry of Ebola Virus Species and Mutants, Which Is Blocked by Recombinant TIM-1 Protein. <i>Microbiology Spectrum</i> , 2022, 10, e0221221.	1.2	3
122	Regulation and quality evaluation system for HIV diagnostics in China. <i>Biologicals</i> , 2016, 44, 111-116.	0.5	2
123	Prevalence of Hepatitis E Virus Infection among Laboratory Rabbits in China. <i>Pathogens</i> , 2021, 10, 780.	1.2	2
124	In Vivo Bioluminescent Imaging of Marburg Virus in a Rodent Model. <i>Methods in Molecular Biology</i> , 2020, 2081, 177-190.	0.4	2
125	Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal. <i>Archives of Virology</i> , 2022, 167, 459-470.	0.9	2
126	Simultaneous determination of capsid proteins in nine-valent human papilloma virus vaccines by liquid chromatography tandem mass spectrometry. <i>Journal of Separation Science</i> , 2021, 44, 557-564.	1.3	1



#	ARTICLE	IF	CITATIONS
127	High-Throughput Screening and Identification of Human Adenovirus Type 5 Inhibitors. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 767578.	1.8	1